---
title: "SARMs vs Steroids vs Peptides: Family Differences"
description: "The three families explained: mechanism of action, suppression, PCT need, and who each family is built for."
lang: en
dateModified: 2026-05-23
canonical: https://anaprotokol.com/en/guides/sarms-vs-steroids-vs-peptides
---

# SARMs vs Steroids vs Peptides: Family Differences

It is convenient to lump everything under one word — **"gear"** — but steroids, SARMs, peptides and HGH are pharmacologically distinct families. They do not share the same mechanism, the same side-effect profile, or the same post-cycle constraints. Understanding **what really separates SARMs, steroids, peptides and HGH** is the first step before picking anything: these are not 'stronger or weaker versions' of the same product. They hit different receptors and different pathways, and each one needs a different management strategy.

This guide is the head of the compound families cluster. It draws the big map — receptors, HPTA suppression, whether a [PCT](/en/guides/pct-protocol-guide) is needed or not, time-to-effect, what kind of bloods you should plan — and hands off to the dedicated guide for each family: [SARMs](/en/guides/sarms-complete-guide), [peptides for bodybuilding](/en/guides/peptides-for-bodybuilding), [HGH](/en/guides/hgh-bodybuilding-guide), [GHRP and GHRH peptides](/en/guides/ghrp-ghrh-peptides-guide), [recovery peptides](/en/guides/bpc-157-tb-500-recovery-peptides).

## Why these families need to be separated before any decision

Most comparison articles online rank these compounds on a single axis — 'stronger or weaker', 'safer or riskier'. That linear view is misleading. An anabolic steroid, a SARM and a recovery peptide are not substitutes for each other: they solve different problems, act on different biological targets, and expose users to different risks. Confusing them leads to protocol errors — a beginner who picks HGH thinking it is 'softer than testosterone' is making a category mistake; an athlete who stacks SARMs assuming there will be no suppression is making the same kind of error.

A useful read sits on four axes: the **biological target** (which receptor or hormonal pathway), the **HPTA suppression** (whether endogenous testosterone production gets shut down), the **time-to-effect** (a few days, a few weeks, several months), and the **monitoring required** (which bloods, how often). Those four axes structure the table below.

| Family | Main target | HPTA suppression | PCT required | Time to visible effect |
| --- | --- | --- | --- | --- |
| Anabolic steroids | Androgen receptor (all cells) | Total and systematic | Yes — always | 2 to 6 weeks |
| SARMs (Ostarine, LGD, RAD-140) | Androgen receptor (tissue-selective) | Moderate to strong by compound | Yes for LGD/RAD; mini-PCT for Ostarine | 3 to 6 weeks |
| GH secretagogues (MK-677, Ipamorelin) | GHRH/ghrelin receptors (pituitary) | None (no HPTA action) | No | 4 to 12 weeks |
| HGH (recombinant somatropin) | GH receptor then IGF-1 | None on HPTA, but inhibits endogenous GH | No, but slow washout | 3 to 6 months |
| Recovery peptides (BPC-157, TB-500) | Tissue healing pathways | None | No | 1 to 3 weeks |

> This table is a compass, not an equivalence. The 'SARMs' row groups very heterogeneous molecules: the HPTA suppression of Ostarine at 10 mg/day is nothing like RAD-140 at 20 mg/day. Same for 'peptides', which covers GH secretagogues (Ipamorelin) and tissue agents (BPC-157) with strictly nothing in common pharmacologically.

## Anabolic steroids: the reference family

Anabolic-androgenic steroids (AAS) are synthetic derivatives of testosterone that bind to the androgen receptor found in most tissues of the body [1]. That ubiquity explains both their effectiveness (muscle gain, strength, recovery) and their side-effect profile (skin, hair, prostate, cardiovascular, liver for orals, HPTA suppression). It is also the most thoroughly documented family — several decades of clinical, medical and community track record.

### Structural characteristics

- **Total and systematic HPTA suppression.** Every cycle shuts down endogenous testosterone production and stops spermatogenesis [8]. [PCT](/en/guides/pct-protocol-guide) is non-negotiable.
- **Aromatization for certain compounds.** [Testosterone](/en/molecule/test-enanthate), [Dianabol](/en/molecule/dianabol) and nandrolone aromatize to estradiol — hence the need for estradiol monitoring and sometimes an aromatase inhibitor.
- **Liver toxicity specific to 17α-alkylated orals.** Oral compounds (Dianabol, [Winstrol](/en/molecule/winstrol), [Anadrol](/en/molecule/anadrol), [Anavar](/en/molecule/anavar)) raise AST/ALT and need short windows — see the [liver health and orals](/en/guides/liver-health-oral-steroids) guide.
- **Degraded cardiovascular profile.** HDL drops, hematocrit climbs, sometimes blood pressure rises. The [heart health on cycle](/en/guides/heart-health-on-cycle) guide unpacks the implications.

Who is this family built for? Users who accept the side-effect profile and the PCT requirement, who have 3 to 5 years of structured training behind them, who put the money down for monitoring (bloods before/during/after), and who start with a simple cycle — generally testosterone only. The [first steroid cycle](/en/guides/first-steroid-cycle) guide develops those prerequisites.

## SARMs: the promise of selectivity

SARMs (Selective Androgen Receptor Modulators) are non-steroidal molecules that also bind to the androgen receptor, but with variable affinity across tissues. The original idea: act preferentially on muscle and bone, and little on skin, hair or prostate. The anabolic/androgenic ratio of the main SARMs is indeed much more favorable than testosterone — on paper.

Reality is more nuanced. Tissue selectivity is never total [2], and HPTA suppression is real — moderate for [Ostarine (MK-2866)](/en/molecule/ostarine) at contained doses, marked for [LGD-4033 (Ligandrol)](/en/molecule/lgd-4033) and [RAD-140 (Testolone)](/en/molecule/rad140) at effective doses. PCT is therefore required for LGD and RAD; for Ostarine, a mini-PCT (Nolvadex 20 mg over 4 weeks) is often enough. The [SARMs PCT guide](/en/guides/sarms-pct-guide) walks through that decision.

### The MK-677 and Cardarine special cases

Two molecules get regularly filed under 'SARMs' even though they are not pharmacologically: [MK-677 (Ibutamoren)](/en/molecule/mk677) is a growth hormone secretagogue — it does not touch the androgen receptor and does not suppress the HPTA. [Cardarine (GW-501516)](/en/molecule/cardarine) is a PPARδ agonist — it acts on cellular metabolism and endurance, with no relation to androgens. Classing them as SARMs is a vendor convention, not a pharmacological fact.

> Cardarine is associated with a carcinogenic signal in animal studies at high doses and over long durations. The transposition to humans remains uncertain, but it justifies use in short cycles (under 12 weeks) rather than continuous. See the [SARMs guide](/en/guides/sarms-complete-guide) for the detail.

Product quality is this family's Achilles heel: the SARMs market is less regulated than the historic underground steroid labs, and underdosing, substitution by prohormones and contamination are routinely documented by the few independent analysis labs that look. A SARMs cycle with no bloods (including LH/FSH) cannot tell you whether the product was active or not.

## Peptides: one word, several distinct categories

The word 'peptide' is a chemical category (short chains of amino acids), not a pharmacological one: the molecules that fall under it have completely different biological targets. In bodybuilding, two main groups are useful.

### Growth hormone peptides

The **GHRP** ([Ipamorelin](/en/molecule/ipamorelin), GHRP-2, GHRP-6) and the **GHRH** ([CJC-1295](/en/molecule/cjc1295), Mod GRF 1-29). They stimulate pulsatile growth hormone release from the pituitary. The GHRP + GHRH stack amplifies the natural pulse without disconnecting the axis — IGF-1 climbs, endogenous GH stays regulated [4]. No HPTA suppression, no PCT. The [GHRP/GHRH guide](/en/guides/ghrp-ghrh-peptides-guide) develops the protocol and injection timing.

### Tissue repair peptides

Essentially [BPC-157](/en/molecule/bpc157) and [TB-500](/en/molecule/tb500). They have no hormonal action — they work on the tissue-repair pathways (tendons, ligaments, muscles, mucosa). No suppression, no PCT, a short side-effect profile. The [recovery peptides guide](/en/guides/bpc-157-tb-500-recovery-peptides) explains the BPC + TB stack and the oncology precaution (these peptides stimulate cellular growth and are contraindicated for users with a cancer history).

The full panorama is in the [peptides for bodybuilding](/en/guides/peptides-for-bodybuilding) guide — including the realistic expectations: peptides do not replace a steroid cycle for raw mass, but they open a complementary use (recovery, sleep quality, healing) that is their own.

## HGH: its own category

Recombinant [somatropin (HGH)](/en/molecule/hgh) is neither a steroid nor a peptide in the bodybuilding sense: it is human growth hormone itself, produced by genetic engineering and injected subQ. It acts through the GH receptor and then through hepatic IGF-1 production.

- **IU dosing, not mg.** Typical ranges: 2 to 6 IU/day for anti-aging or recomp use; 6 to 12 IU/day for advanced users. Short half-life (3 to 4 h) but very slow biological effects.
- **Long time-to-effect.** 3 to 6 months to see structural benefits (lean mass, skin quality, joints). No '4 weeks in' satisfaction.
- **Insulin resistance.** GH raises fasting glucose and can induce insulin resistance — glucose monitoring (HbA1c, fasting glucose) is useful, particularly in predisposed users.
- **Cost and source quality.** Authentic pharmaceutical HGH (Pfizer Genotropin, Lilly Humatrope, Novo Nordisk Norditropin) costs a fortune; the underground market is saturated with underdosed or counterfeit products. An 'HGH cycle' with no certainty about source is largely a lost investment.

HGH does not suppress the HPTA and needs no PCT. It does inhibit endogenous GH production during use, which restarts fairly quickly after you stop [5]. The [HGH guide](/en/guides/hgh-bodybuilding-guide) develops the protocol, the bloods to plan, and the precautions.

## Who each family is built for

What follows is not a use recommendation — it is a framing tool to position each family in context. The choice of whether to use any of them is personal, and remains subject to the legal framework of the country of residence and to the advice of a healthcare professional who has been informed.

| User profile | Relevant family | Why |
| --- | --- | --- |
| Absolute beginner looking for a boost | None on performance — training, nutrition, sleep | Natural gains are nowhere near saturated |
| 3-5 years trained, open to PCT and monitoring | Steroids (testosterone only on first cycle) | Best-documented family, solid foundation |
| Intermediate lifter wanting to avoid injections | SARMs (Ostarine on cuts, LGD on bulks) | More modest gains but oral route; still suppressive |
| Injured athlete in recovery | Recovery peptides (BPC-157, TB-500) | Tendon/ligament healing |
| Veteran chasing quality (skin, sleep, joints) | GH secretagogues (Ipamorelin + CJC) or HGH | Mild lipolysis, recovery, anti-aging |
| Post-cycle user wanting better recovery | MK-677 or GHRP/GHRH stack | No HPTA impact |

> Mixing these families 'because you add up the advantages' is a classic mistake. A beginner who adds HGH + SARMs + peptides to a first testosterone cycle multiplies variables without understanding what works or does not. The rule is the opposite: one new compound at a time, on a stable base, with bloods before/during/after.

## Monitoring changes by family

Too many users assume blood work 'is for steroids'. It is not. Each family calls for a specific monitoring protocol — different, but real [7].

| Family | Priority markers | Indicative frequency |
| --- | --- | --- |
| Steroids | Estradiol, testosterone, LH/FSH, hematocrit, HDL/LDL, AST/ALT (orals) | Baseline, mid-cycle, post-PCT |
| SARMs (LGD/RAD) | LH/FSH, testosterone, ALT, lipids | Baseline, end of cycle, post mini-PCT |
| MK-677 | Fasting glucose, HbA1c, IGF-1 | Baseline then quarterly if extended use |
| HGH | IGF-1, fasting glucose, HbA1c, T3/T4 at high doses | Baseline then quarterly |
| Recovery peptides | Annual baseline; no specific marker | Annual |

The global approach and standard windows are detailed in the [blood work on cycle](/en/guides/blood-work-on-cycle) guide and in the [blood test schedule](/en/guides/blood-test-schedule-cycle).

## The most frequent confusions

- **"SARMs do not need a PCT."** False for LGD-4033 and RAD-140 at effective doses. Partially true for Ostarine at contained doses. See the [SARMs PCT guide](/en/guides/sarms-pct-guide).
- **"HGH is softer than a cycle."** HGH has a different risk profile (insulin resistance, carpal tunnel syndrome, internal tissue hypertrophy at high doses) — neither softer nor harsher, just different.
- **"BPC-157 and TB-500 are supplements."** No: they are injectable peptides. The short side-effect profile does not waive the oncology precaution (stimulated cellular growth).
- **"Ipamorelin replaces a cycle."** No: it amplifies the endogenous GH pulse, producing modest recovery and lipolysis effects, unrelated to the muscle gains of a cycle.
- **"Cardarine + Ostarine = risk-free cutting."** The animal carcinogenic controversy on Cardarine is unresolved. Short cycles only, no continuous use.

The antidote to these confusions is the same as for the rest: frame the decision on real pharmacology (not vendor marketing), accept measurement (bloods before/during/after), and move one product at a time. The doctrine is summarized in the [harm reduction on cycle](/en/guides/harm-reduction-steroids) guide.

## FAQ

### Are SARMs really safer than steroids?

SARMs have a different side-effect profile — not a non-existent one. They do not aromatize (so no classic gyno), are less androgenic (less acne, less hair impact for most users) and are not hepatotoxic in the 17α-alkylated oral sense. But they suppress the HPTA (moderately to strongly depending on the compound), can degrade the lipid profile, and the clinical track record is much shorter than for steroids. Long-term safety remains poorly documented.

### Can you combine HGH, steroids and peptides in the same cycle?

Technically yes — that is even a known protocol among certain advanced athletes. Practically, it multiplies variables and risks without any clear benefit for a user who has not yet stabilized a clean testosterone-only cycle with proper monitoring. The rule that reduces problems the most: add one product at a time, on a stable base, with bloods before and after.

### Do peptides like BPC-157 or Ipamorelin need a PCT?

No. None of the common bodybuilding peptides (BPC-157, TB-500, Ipamorelin, CJC-1295, MK-677) suppress the HPTA. No PCT is required. The main precaution for recovery peptides is oncologic (contraindicated with a cancer history); for GH secretagogues, it is metabolic (glucose monitoring on extended use).

### At what level should you consider one family over another?

It is a personal question, but a few landmarks: 3 to 5 years of structured training, sustained nutrition and sleep, and normal baseline bloods are the common prerequisites for every performance family. Beyond that, the choice depends on the goal (mass vs cutting vs recovery vs anti-aging), the relationship to monitoring you are willing to maintain, and your personal risk tolerance. The [first steroid cycle](/en/guides/first-steroid-cycle) guide details the prerequisites for the steroid route, which remains the most documented.